Ítem
Acceso Abierto
Incident cervical HPV infections in young women: Transition probabilities for CIN and infection clearance
| dc.creator | Insinga R.P. | spa |
| dc.creator | Perez, Gonzalo | spa |
| dc.creator | Wheeler C.M. | spa |
| dc.creator | Koutsky L.A. | spa |
| dc.creator | Garland S.M. | spa |
| dc.creator | Leodolter S. | spa |
| dc.creator | Joura E.A. | spa |
| dc.creator | Ferris D.G. | spa |
| dc.creator | Steben M. | spa |
| dc.creator | Hernandez-Avila M. | spa |
| dc.creator | Brown D.R. | spa |
| dc.creator | Elbasha E. | spa |
| dc.creator | Muñoz N. | spa |
| dc.creator | Paavonen J. | spa |
| dc.creator | Haupt R.M. | spa |
| dc.date.accessioned | 2020-05-26T00:03:49Z | |
| dc.date.available | 2020-05-26T00:03:49Z | |
| dc.date.created | 2011 | spa |
| dc.description.abstract | Background: We describe transition probabilities for incident human papillomavirus (HPV) 16/18/31/33/35/45/52/58/59 infections and cervical intraepithelial neoplasia (CIN) 1 lesions. Methods: Women ages 16 to 23 years underwent cytology and cervical swab PCR testing for HPV at approximately 6-month intervals for up to 4 years in the placebo arm of an HPV vaccine trial. The cumulative proportion of incident HPV infections with diagnosed CIN, clearing (infection undetectable), or persisting without CIN, were estimated. Results: Most incident infections cleared, without detection of CIN, ranging at 36 months from 66.9% for HPV31 to 91.1% for HPV59. There was little variation in the 36-month proportion of incident HPV16, 18, and 31 infections followed by a CIN1 lesion positive for the relevant HPV type (range 16.7%-18.6%), with lower risks for HPV59 (6.4%) and HPV33 (2.9%). Thirty-six-month transition probabilities for CIN2 ranged across types from 2.2% to 9.1%; however, the number of events was generally too small for statistically significant differences to be seen across types for this endpoint, or CIN3. Conclusions: Some incident HPV types appear more likely to result in diagnosed CIN1 than others. The relative predominance of HPV16, vis-à-vis some other high-risk HPV types (e.g., HPV33) in prevalent CIN2/3, appears more directly associated with relatively greater frequency of incident HPV16 infections within the population, than a higher risk of infection progression to CIN2/3. Impact: Nearly all incident HPV infections either manifest as detectable CIN or become undetectable within 36 months. Some HPV types (e.g., 16 and 33) appear to have similar risk of CIN2/3 despite widely varied incidence. ©2011 AACR. | eng |
| dc.format.mimetype | application/pdf | |
| dc.identifier.doi | https://doi.org/10.1158/1055-9965.EPI-10-0791 | |
| dc.identifier.issn | 10559965 | |
| dc.identifier.uri | https://repository.urosario.edu.co/handle/10336/23632 | |
| dc.language.iso | eng | spa |
| dc.relation.citationEndPage | 296 | |
| dc.relation.citationIssue | No. 2 | |
| dc.relation.citationStartPage | 287 | |
| dc.relation.citationTitle | Cancer Epidemiology Biomarkers and Prevention | |
| dc.relation.citationVolume | Vol. 20 | |
| dc.relation.ispartof | Cancer Epidemiology Biomarkers and Prevention, ISSN:10559965, Vol.20, No.2 (2011); pp. 287-296 | spa |
| dc.relation.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-79951656791&doi=10.1158%2f1055-9965.EPI-10-0791&partnerID=40&md5=9cbafdec0919c1bce68dc4a6e7f6b947 | spa |
| dc.rights.accesRights | info:eu-repo/semantics/openAccess | |
| dc.rights.acceso | Abierto (Texto Completo) | spa |
| dc.source.instname | instname:Universidad del Rosario | spa |
| dc.source.reponame | reponame:Repositorio Institucional EdocUR | spa |
| dc.subject.keyword | Placebo | spa |
| dc.subject.keyword | Wart virus vaccine | spa |
| dc.subject.keyword | Adolescent | spa |
| dc.subject.keyword | Adult | spa |
| dc.subject.keyword | Article | spa |
| dc.subject.keyword | Cancer diagnosis | spa |
| dc.subject.keyword | Cancer incidence | spa |
| dc.subject.keyword | Controlled clinical trial | spa |
| dc.subject.keyword | Controlled study | spa |
| dc.subject.keyword | Cytology | spa |
| dc.subject.keyword | Female | spa |
| dc.subject.keyword | Human | spa |
| dc.subject.keyword | Human papillomavirus type 16 | spa |
| dc.subject.keyword | Human papillomavirus type 18 | spa |
| dc.subject.keyword | Human papillomavirus type 31 | spa |
| dc.subject.keyword | Human papillomavirus type 33 | spa |
| dc.subject.keyword | Human papillomavirus type 35 | spa |
| dc.subject.keyword | Human papillomavirus type 45 | spa |
| dc.subject.keyword | Human papillomavirus type 52 | spa |
| dc.subject.keyword | Human papillomavirus type 58 | spa |
| dc.subject.keyword | Human papillomavirus type 59 | spa |
| dc.subject.keyword | Infection risk | spa |
| dc.subject.keyword | Nonhuman | spa |
| dc.subject.keyword | Papillomavirus infection | spa |
| dc.subject.keyword | Pathogen clearance | spa |
| dc.subject.keyword | Polymerase chain reaction | spa |
| dc.subject.keyword | Priority journal | spa |
| dc.subject.keyword | Randomized controlled trial | spa |
| dc.subject.keyword | Uterine cervix carcinoma in situ | spa |
| dc.subject.keyword | Adolescent | spa |
| dc.subject.keyword | Adult | spa |
| dc.subject.keyword | Cervical intraepithelial neoplasia | spa |
| dc.subject.keyword | Cervix uteri | spa |
| dc.subject.keyword | Double-blind method | spa |
| dc.subject.keyword | Female | spa |
| dc.subject.keyword | Follow-up studies | spa |
| dc.subject.keyword | Humans | spa |
| dc.subject.keyword | Incidence | spa |
| dc.subject.keyword | International agencies | spa |
| dc.subject.keyword | Papillomaviridae | spa |
| dc.subject.keyword | Papillomavirus infections | spa |
| dc.subject.keyword | Papillomavirus vaccines | spa |
| dc.subject.keyword | Placebos | spa |
| dc.subject.keyword | Prevalence | spa |
| dc.subject.keyword | Prognosis | spa |
| dc.subject.keyword | Risk factors | spa |
| dc.subject.keyword | Survival rate | spa |
| dc.subject.keyword | Uterine cervical neoplasms | spa |
| dc.subject.keyword | Young adult | spa |
| dc.title | Incident cervical HPV infections in young women: Transition probabilities for CIN and infection clearance | spa |
| dc.type | article | eng |
| dc.type.hasVersion | info:eu-repo/semantics/publishedVersion | |
| dc.type.spa | Artículo | spa |
Archivos
Bloque original
1 - 1 de 1
Cargando...
- Nombre:
- 287-full.pdf
- Tamaño:
- 210.54 KB
- Formato:
- Adobe Portable Document Format
- Descripción:



